Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 5, 2016, Pages 1054-1066

  Hugenholtz, G C G ^a   Macrae, F ^b   Adelmeijer, J ^a   Dulfer, S ^a   Porte, R J ^a   Lisman, T ^a   Ariens R A S ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Fibrinogen; Hemostasis; Liver cirrhosis; Oxidative stress; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 13; CARBONYL DERIVATIVE; FIBRINOGEN; MALONALDEHYDE; THROMBOPLASTIN; COAGULATING AGENT; FIBRIN; HEMOSTATIC AGENT; OXYGEN;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CLOT PERMEABILITY; CLOTTING RATE; COMORBIDITY; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSFIBRINOGENEMIA; FEMALE; FIBER THICKNESS; FIBRIN CLOT STRUCTURE; FIBRIN DENSITY; FIBRINOGEN BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; IN VITRO STUDY; LASER SCANNING CONFOCAL MICROSCOPY; LIVER CIRRHOSIS; MALE; MEMBRANE PERMEABILITY; MIDDLE AGED; OXIDATION; OXIDATIVE MODIFICATION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; RISK; SCANNING ELECTRON MICROSCOPY; SMOKING; STRUCTURE ACTIVITY RELATION; THROMBOTIC RISK; TURBIDITY; BLOOD; BLOOD CLOTTING TEST; CHEMISTRY; FIBROSIS; NORMAL HUMAN; PERMEABILITY; THROMBOSIS;

ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; COAGULANTS; FACTOR XIII; FEMALE; FIBRIN; FIBRINOGEN; FIBROSIS; HEALTHY VOLUNTEERS; HEMOSTASIS; HEMOSTATICS; HUMANS; MALE; MALONDIALDEHYDE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; OXYGEN; PERMEABILITY; THROMBOSIS;

EID: 84960158618     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13278     Document Type: Article

References (59)

1. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878-85.
2. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.
3. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, Hoffman MR, Ikura Y, Caldwell SH. Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008; 6: 2-9.
4. Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009; 13: 117-26.
5. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008; 6: 1336-43.
6. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253.
7. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, Colombo M, Mannucci PM. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-11.
8. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell'Era A, Iannuzzi F, Aghemo A, Mannucci PM. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52: 249-55.
9. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
10. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013; 58: 752-61.
11. Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
12. Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-7.
13. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-8.
14. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-73.
15. Undas A, Plicner D, Stepien E, Drwila R, Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost 2007; 5: 1988-90.
16. Martinez J, Palascak JE, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest. 1978; 61: 535-8.
17. Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61: 1196-202.
18. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, De Groot PG. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
19. Potze W, Adelmeijer J, Porte RJ, Lisman T. Preserved clot formation detected by the thrombodynamics analyzer in patients with cirrhosis. Thromb Res 2015; 135: 1012-6.
20. Martinez M, Weisel JW, Ischiropoulos H. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. Free Radic Biol Med 2013; 65: 411-8.
21. Olinescu RM, Kummerow FA. Fibrinogen is an efficient antioxidant. J Nutr Biochem 2001; 12: 162-9.
22. Choi J, Ou JH. Mechanisms of liver injury. III. oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006; 290: G847-51.
23. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306.
24. Zima T, Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res 2005; 29: 110S-5S.
25. Bomzon A, Ljubuncic P. Oxidative stress and vascular smooth muscle cell function in liver disease. Pharmacol Ther 2001; 89: 295-308.
26. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28: 110-22.
27. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014; 9: e88390.
28. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-206.
29. Smith EL, Cardinali B, Ping L, Ariens RA, Philippou H. Elimination of coagulation factor XIII from fibrinogen preparations. J Thromb Haemost 2013; 11: 993-5.
30. Scott DJ, Prasad P, Philippou H, Rashid ST, Sohrabi S, Whalley D, Kordowicz A, Tang Q, West RM, Johnson A, Woods J, Ajjan RA, Ariens RA. Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size. Arterioscler Thromb Vasc Biol 2011; 31: 3004-10.
31. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
32. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-42.
33. Woodhead JL, Nagaswami C, Matsuda M, Arocha-Pinango CL, Weisel JW. The ultrastructure of fibrinogen caracas II molecules, fibers, and clots. J Biol Chem 1996; 271: 4946-53.
34. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
35. Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariens RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009; 29: 712-7.
36. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106: 4176-83.
37. Westerkamp AC, Mahboub P, Meyer SL, Hottenrott M, Ottens PJ, Wiersema-Buist J, Gouw AS, Lisman T, Leuvenink HG, Porte RJ. End-ischemic machine perfusion reduces bile duct injury in donation after circulatory death rat donor livers independent of the machine perfusion temperature. Liver Transpl 2015; 21: 1300-11.
38. Allan P, Uitte de Willige S, Abou-Saleh RH, Connell SD, Ariens RA. Evidence that fibrinogen gamma' directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost 2012; 10: 1072-80.
39. Pieters M, Kotze RC, Jerling JC, Kruger A, Ariens RA. Evidence that fibrinogen gamma' regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black africans. Blood 2013; 121: 3254-60.
40. Hugenholtz GC, Northup PG, Porte RJ, Lisman T. Is there a rationale for treatment of chronic liver disease with antithrombotic therapy? Blood Rev 2015; 29: 127-36.
41. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M. Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
42. Inada Y, Hessel B, Blomback B. Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim Biophys Acta 1978; 532: 161-70.
43. Shimizu A, Saito Y, Inada Y. Distinctive role of histidine-16 of the B beta chain of fibrinogen in the end-to-end association of fibrin. Proc Natl Acad Sci U S A. 1986; 83: 591-3.
44. Weigandt KM, White N, Chung D, Ellingson E, Wang Y, Fu X, Pozzo DC. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen. Biophys J 2012; 103: 2399-407.
45. Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121: 1712-9.
46. Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 2010; 16: 7-12.
47. Kremers RM, Wagenvoord RJ, Hemker HC. The effect of fibrin(ogen) on thrombin generation and decay. Thromb Haemost 2014; 112: 486-94.
48. Paton LN, Mocatta TJ, Richards AM, Winterbourn CC. Increased thrombin-induced polymerization of fibrinogen associated with high protein carbonyl levels in plasma from patients post myocardial infarction. Free Radic Biol Med 2010; 48: 223-9.
49. Domingues MM, Macrae FL, Duval C, McPherson HR, Bridge KI, Ajjan RA, Ridger VC, Connell SD, Philippou H, Ariëns RA. Thrombin and fibrinogen γ' impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood. 2016; 127: 487-95.
50. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102: 535-40.
51. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, Tripodi A, Trotter JF, Valla DC, Porte RJ. Coagulation in Liver Disease Study Group. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53: 362-71.
52. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-8.; quiz 1680.
53. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9: 1713-23.
54. Becatti M, Marcucci R, Bruschi G, Taddei N, Bani D, Gori AM, Giusti B, Gensini GF, Abbate R, Fiorillo C. Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction. Arterioscler Thromb Vasc Biol 2014; 34: 1355-61.
55. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, Stamer S, Liebler DC, Koliakos G, Heijnen HF, Fitzgerald GA, Weisel JW, Ischiropoulos H. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 2008; 283: 33846-53.
56. Barua RS, Sy F, Srikanth S, Huang G, Javed U, Buhari C, Margosan D, Ambrose JA. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol 2010; 30: 75-9.
57. Martinez M, Cuker A, Mills A, Lightfoot R, Fan Y, Tang WH, Hazen SL, Ischiropoulos H. Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism. Free Radic Biol Med 2012; 53: 230-6.
58. Miniati M, Fiorillo C, Becatti M, Monti S, Bottai M, Marini C, Grifoni E, Formichi B, Bauleo C, Arcangeli C, Poli D, Nassi PA, Abbate R, Prisco D. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181: 992-6.
59. Undas A, Nowakowski T, Ciesla-Dul M, Sadowski J. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011; 215: 481-6.